Table 4.
Baseline demographic and disease characteristics
| PASCET-PI group (n = 37) | CAU group (n = 33) | p value | |
|---|---|---|---|
| Demographic status | |||
| Male, n (%) | 10 (27.0) | 12 (36.4) | .401a |
| Age, mean (SD), years | 18.62 (4.27) | 17.69 (4.82) | .393b |
| SES, n (%) | |||
| Low | 8 (21.6) | 4 (12.9) | .348a |
| Middle | 15 (40.5) | 10 (32.3) | |
| High | 14 (37.8) | 17 (54.8) | |
| Ethnicity, n (%) (n = 64) | |||
| Dutch/Western | 30 (81.1) | 25 (80.6) | .749a |
| Other | 7 (18.9) | 6 (19.4) | |
| Included on, n (%) | |||
| Anxiety | 30 (81.1) | 20 (60.6) | .070a |
| Depression | 0 (0.0) | 3 (9.1) | |
| Both | 7 (18.9) | 10 (30.3) | |
| IBD subtype, n (%) | |||
| Crohn’s disease | 18 (48.6) | 18 (54.5) | .808a |
| Ulcerative colitis | 14 (37.8) | 12 (36.4) | |
| IBD-U | 5 (13.5) | 3 (9.1) | |
| Paris classification at diagnosis, n (%) | |||
| CD: location (n = 36)† | |||
| L1 | 4 (22.2) | 2 (11.1) | .813a |
| L2 | 4 (22.2) | 4 (22.2) | |
| L3 | 6 (33.3) | 8 (44.4) | |
| + L4a/L4b | 4 (22.2) | 4 (22.2) | |
| CD: behavior (n = 36) | |||
| Non-stricturing, non-penetrating | 18 (100.0) | 16 (88.9) | .243c |
| Stricturing, penetrating, or both | 0 (0.0) | 2 (11.1) | |
| UC: extent (n = 34)‡ | |||
| Limited: E1 + E2 | 11 (57.9) | 4 (26.7) | .069a |
| Extensive: E3 + E4 | 8 (42.1) | 11 (73.3) | |
| UC: severity | |||
| Never severe | 18 (94.7) | 11 (73.3) | .104c |
| Ever severe | 1 (5.3) | 4 (26.7) | |
| Clinical disease activity, n (%) | |||
| Remission | 27 (73.0) | 26 (78.8) | .571a |
| Mild | 10 (27.0) | 7 (21.2) | |
| Disease duration, median, years | 2.59 | 1.17 | .039d |
| IBD Medications, n (%) | |||
| Aminosalicylates | 18 (48.6) | 12 (36.4) | .300a |
| Immunomodulators | 16 (43.2) | 16 (48.5) | .660a |
| Biologicals | 8 (21.6) | 12 (36.4) | .173a |
| Corticosteroids§ | 2 (5.4) | 5 (15.2) | .170c |
| Enemas | 3 (8.1) | 1 (3.0) | .352c |
| No medication | 2 (5.4) | 1 (3.0) | .543c |
PASCET-PI primary and secondary control enhancement training for physical illness, CAU care-as-usual, SD standard deviation, IBD inflammatory bowel disease, IBD-U inflammatory bowel disease unclassified, SES socioeconomic status
aChi-square
bANOVA
cFisher’s Exact test
dMann–Whitney test | *UC includes IBD-U patients, †L1: ileocecal, L2: colonic, L3: ileocolonic, L4a: upper gastrointestinal tract proximal, and L4b distal from Treitz ligament ‡E1: proctitis, E2: left-sided colitis distal of splenic flexure, E3: extensive colitis distal of hepatic flexure, E4: pancolitis §prednisone (oral and intravenous) and budesonide (oral)